Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Bolt Biotherapeutics (BOLT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: BOLT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $40
1 Year Target Price $40
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -42.55% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.35M USD | Price to earnings Ratio - | 1Y Target Price 40 |
Price to earnings Ratio - | 1Y Target Price 40 | ||
Volume (30-day avg) 4 | Beta 0.91 | 52 Weeks Range 5.20 - 15.60 | Updated Date 07/5/2025 |
52 Weeks Range 5.20 - 15.60 | Updated Date 07/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -33.2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -991.41% |
Management Effectiveness
Return on Assets (TTM) -34.57% | Return on Equity (TTM) -83.92% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -2780455 | Price to Sales(TTM) 3.12 |
Enterprise Value -2780455 | Price to Sales(TTM) 3.12 | ||
Enterprise Value to Revenue 64.2 | Enterprise Value to EBITDA 0.93 | Shares Outstanding 1916980 | Shares Floating 1438199 |
Shares Outstanding 1916980 | Shares Floating 1438199 | ||
Percent Insiders 2.26 | Percent Institutions 46.17 |
Upturn AI SWOT
Bolt Biotherapeutics
Company Overview
History and Background
Bolt Biotherapeutics was founded in 2015. It focuses on developing immuno-oncology therapies to harness the power of the immune system to fight cancer. The company has advanced its Boltbodyu2122 Immune-Stimulating Antibody Conjugate (ISAC) platform, designed to redirect the immune system to eliminate tumor cells.
Core Business Areas
- Boltbodyu2122 ISAC Platform Development: Development of novel immunotherapies based on the Boltbodyu2122 ISAC platform, which conjugates antibodies targeting tumor-associated antigens with immune-stimulating agents.
- Clinical Trials and Research: Conducting preclinical research and clinical trials to evaluate the safety and efficacy of their ISAC product candidates in various cancer types.
Leadership and Structure
Dr. Elizabeth Tallett serves as the Chair of the Board of Directors. The executive team is led by Randall C. Schatzman, Ph.D., President and Chief Executive Officer. The company structure includes research, development, clinical operations, and business development departments.
Top Products and Market Share
Key Offerings
- BDTX-1535: BDTX-1535 is Bolt's lead Boltbody ISAC candidate targeting solid tumors expressing HER2. It is currently in Phase 1/2 clinical trials. Competitors in the HER2-targeted therapy space include Roche (Herceptin, Perjeta, Kadcyla) and AstraZeneca/Daiichi Sankyo (Enhertu). Market share data for this specific candidate is not publicly available as it is still in clinical development.
- BDT6001: BDT6001 is targeting solid tumors expressing EGFR. It is currently in Phase 1/2 clinical trials. Competitors in the EGFR-targeted therapy space include Eli Lilly(Erbitux) and AstraZeneca(Tagrisso). Market share data for this specific candidate is not publicly available as it is still in clinical development.
Market Dynamics
Industry Overview
The immuno-oncology market is experiencing significant growth, driven by advances in understanding the interaction between the immune system and cancer. The field includes checkpoint inhibitors, CAR-T cell therapy, and antibody-drug conjugates. Competition is intense, with numerous companies developing novel immunotherapies.
Positioning
Bolt Biotherapeutics is positioned in the immuno-oncology market with its proprietary Boltbodyu2122 ISAC platform. Their competitive advantage lies in their approach to redirecting the immune system specifically to tumor cells, potentially minimizing off-target effects.
Total Addressable Market (TAM)
The immuno-oncology market is expected to reach hundreds of billions of dollars in the coming years. Bolt is positioned to address a segment of this TAM by developing therapies for solid tumors. Exact TAM is dependent on the success of their clinical trials and the specific indications they pursue.
Upturn SWOT Analysis
Strengths
- Proprietary Boltbodyu2122 ISAC platform technology
- Strong scientific team and experienced leadership
- Potential for targeted immune activation and reduced toxicity
- Focus on addressing unmet needs in solid tumors
Weaknesses
- Early-stage clinical development (high risk)
- Reliance on single technology platform
- Limited financial resources compared to larger competitors
- Dependence on collaborations and partnerships
Opportunities
- Expanding pipeline with new Boltbodyu2122 ISAC candidates
- Partnering with larger pharmaceutical companies for development and commercialization
- Exploring new indications for existing product candidates
- Advancements in tumor microenvironment research
Threats
- Clinical trial failures
- Competition from established immuno-oncology therapies
- Regulatory hurdles and delays
- Patent challenges
Competitors and Market Share
Key Competitors
- LLY
- AZN
- BMY
- MRK
- PFE
- NVS
Competitive Landscape
Bolt Biotherapeutics competes in the broader immuno-oncology space. Its advantage lies in its Boltbody ISAC platform, but it faces competition from established players with approved therapies and larger financial resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by advancing preclinical programs into clinical trials.
Future Projections: Future growth is dependent on clinical trial outcomes and potential partnerships.
Recent Initiatives: Recent initiatives include advancing BDTX-1535 and BDT6001 to Phase 1/2 clinical trials, and forming strategic partnerships.
Summary
Bolt Biotherapeutics is an early-stage immuno-oncology company with a promising Boltbody ISAC platform. The company is heavily reliant on successful clinical trial outcomes. Potential partnerships and further pipeline development will be crucial for future growth. Competition in the immuno-oncology market is intense and the company's success hinges on its ability to differentiate its approach.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is estimated and may not be precise. Clinical trial outcomes are uncertain, and the company's future performance is subject to various risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bolt Biotherapeutics
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2021-02-05 | CEO, CFO, President, Secretary & Director Mr. William P. Quinn | ||
Sector Healthcare | Industry Biotechnology | Full time employees 52 | Website https://www.boltbio.com |
Full time employees 52 | Website https://www.boltbio.com | ||
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc.; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.